81227 Cyp2c9 gene com variants
Also known as: CYP2C9 pharmacogenetic panel, CYP2C9 variant testing
Molecular analysis of the CYP2C9 gene to identify common pharmacogenetic variants affecting warfarin metabolism and dosing requirements.
In Plain Language
blood thinner gene test; warfarin sensitivity testing
Clinical Context
Used to guide warfarin dosing and monitoring by identifying patients who are CYP2C9 poor metabolizers requiring dose adjustments.
RVU Information
CPT 81227 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Lab and pathology codes require an order from the treating provider with clinical indication. For molecular pathology and genetic testing, document the specific analytes tested and clinical rationale.
How This Code Compares
This code has a work RVU of 0.00, meaning it does not have a physician work component assigned by CMS. In the Pathology & Lab category, 94% of codes share this characteristic.
Specialties
Frequently Asked Questions
What is CPT code 81227?
CPT 81227 (Cyp2c9 gene com variants) is a Pathology & Lab code. Molecular analysis of the CYP2C9 gene to identify common pharmacogenetic variants affecting warfarin metabolism and dosing requirements.
Who uses CPT code 81227?
CPT 81227 is used by Pathology, Pharmacology, Clinical Genetics. Used to guide warfarin dosing and monitoring by identifying patients who are CYP2C9 poor metabolizers requiring dose adjustments.
When is CPT 81227 used?
Used to guide warfarin dosing and monitoring by identifying patients who are CYP2C9 poor metabolizers requiring dose adjustments.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.